Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Greg L Beilhartz"'
Autor:
Shivneet K Gill, Seiji N Sugiman-Marangos, Greg L Beilhartz, Elizabeth Mei, Mikko Taipale, Roman A Melnyk
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 10, Pp 2638-2651 (2024)
Abstract Targeted intracellular delivery of therapeutic proteins remains a significant unmet challenge in biotechnology. A promising approach is to leverage the intrinsic capabilities of bacterial toxins like diphtheria toxin (DT) to deliver a potent
Externí odkaz:
https://doaj.org/article/0fb3cc127d66415ca18817cfe9e28262
Autor:
John Tam, Therwa Hamza, Bing Ma, Kevin Chen, Greg L. Beilhartz, Jacques Ravel, Hanping Feng, Roman A. Melnyk
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Clostridium difficile causes diarrhea and colitis by producing up to three different protein toxins. Here, Tam et al. show that an anthelmintic drug, niclosamide, inhibits the pathogenesis of all three toxins by targeting a host process required for
Externí odkaz:
https://doaj.org/article/25196c5f6826491d89346cd290d949ba
Autor:
Marco Biancucci, David Gius, Minyoung Park, Matthew B. Kieffer, Karla J. F. Satchell, Vania Vidimar, Greg L. Beilhartz, Roman A. Melnyk
Publikováno v:
Proc Natl Acad Sci U S A
Significance RAS oncoproteins have long been considered among the most elusive drug targets in cancer research. At issue is the lack of accessible drug-binding sites and the extreme affinity for GTP. Covalent inhibitors against the KRAS G12C mutant h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6263d7d9d88fd2101c65e58f686a4f51
https://doi.org/10.1073/pnas.2000312117
https://doi.org/10.1073/pnas.2000312117
Autor:
Greg L. Beilhartz, Matthias Götte
Publikováno v:
Viruses, Vol 2, Iss 4, Pp 900-926 (2010)
Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of acquired immunodeficiency syndrome (AIDS), it has encouraged much research into antiviral compounds. The reverse transcriptase (RT) of HIV has been a main target
Externí odkaz:
https://doaj.org/article/9ddf6e13062e448d88919202d147636f
Autor:
Seiji Sugiman-Marangos, Dongxia Zhou, Greg L. Beilhartz, Berge A. Minassian, Rong Hua, Xiaochu Zhao, Peter K. Kim, Roman A. Melnyk, James M. Rini
Publikováno v:
Science Advances
Engineering lysosomal enzymes to bind the diphtheria toxin receptor with high affinity increases uptake into cells and tissues.
Enzyme replacement therapy, in which a functional copy of an enzyme is injected either systemically or directly into
Enzyme replacement therapy, in which a functional copy of an enzyme is injected either systemically or directly into
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ee168b2381bfee9af17d42e299d21af
https://doi.org/10.1126/sciadv.abb0385
https://doi.org/10.1126/sciadv.abb0385
Autor:
Daniel Schramek, Hunsang Lee, Greg L. Beilhartz, Mikko Taipale, Roman A. Melnyk, Hong Cui, Swetha Raman, Jean-Philippe Julien, John L. Rubinstein, Iga Kucharska, Huazhu Liang, Mandy H. Y. Lam
Publikováno v:
Cell
Summary Pathogenic clostridial species secrete potent toxins that induce severe host tissue damage. Paeniclostridium sordellii lethal toxin (TcsL) causes an almost invariably lethal toxic shock syndrome associated with gynecological infections. TcsL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af189ff005625d3733ded3bff46d472c
http://europepmc.org/articles/PMC7316060
http://europepmc.org/articles/PMC7316060
Autor:
Jinkai Teo, Greg L. Beilhartz, Khong Ming Peh, Simon Ng, Charles W. Johannes, Regina Khoo, Shih Chieh Chang, Brian Henry, Roman A. Melnyk, Anthony W. Partridge, Shuhui Lim, David P. Lane, Christopher J. Brown
Publikováno v:
Proc Natl Acad Sci U S A
Targeted degradation approaches such as proteolysis targeting chimeras (PROTACs) offer new ways to address disease through tackling challenging targets and with greater potency, efficacy, and specificity over traditional approaches. However, identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58da3ece40dbb497774365ec4bac5390
https://europepmc.org/articles/PMC7084165/
https://europepmc.org/articles/PMC7084165/
Autor:
Roman A. Melnyk, Seiji Sugiman-Marangos, Xiaochu Zhao, Greg L. Beilhartz, Rong Hua, Berge A. Minassian, James M. Rini, Dongxia Zhou, Peter K. Kim
Lysosomal storage diseases are a group of over 70 inherited genetic diseases caused by a defect or deficiency in a lysosomal protein. Enzyme replacement therapy, in which a functional copy of the defective enzyme is injected either systemically or di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c377b117722c303616f286ecf51737c
Publikováno v:
Biochemical Pharmacology. 142:13-20
Despite enormous efforts, achieving efficacious levels of proteins inside mammalian cells remains one of the greatest challenges in biologics-based drug discovery and development. The inability of proteins to readily cross biological membranes preclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a701ec959da3de7ce6bc229691d2c6
https://doi.org/10.1016/j.bcp.2017.04.009
https://doi.org/10.1016/j.bcp.2017.04.009
Autor:
David Gius, Vania Vidimar, Greg L. Beilhartz, Karla J. F. Satchell, Marco Biancucci, Minyoung Park, Matthew B. Kieffer, Roman A. Melnyk
SummaryDespite nearly four decades of effort, broad inhibition of oncogenic RAS using small molecule approaches has proven to be a major challenge. Here we describe the development of a novel pan-RAS biologic inhibitor comprised of the RAS-RAP1-speci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d02089008694c63336816327b9eca870
https://doi.org/10.1101/2019.12.17.880187
https://doi.org/10.1101/2019.12.17.880187